Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NEU-411 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| NEU-411 | EXPERIMENTAL | Orally-administered NEU-411 |
| Placebo | PLACEBO_COMPARATOR | Orally-administered matching placebo |
| Name | Type | Description |
|---|---|---|
| NEU-411 | DRUG | NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity |
| Placebo | OTHER | Orally-administered matched placebo |
Inclusion Criteria: 1. Aged 40-80 years at time of screening, inclusive 2. Diagnosis of clinically established or clinically probable Parkinson's Disease (PD) 3. LRRK2-driven PD using the investigational companion diagnostic genetic test (CDx) 4. Modified Hoehn and Yahr (mH\&Y) of 1 to 2.5 Exclusi...
Top 20 of 22 competitors
NEU-411 is an investigational small molecule being developed for the treatment of early Parkinson's disease. It is currently being studied in a Phase 2 clinical trial in patients who test positive for a companion diagnostic biomarker. The drug is administered as an oral therapy.
NEU-411 is being developed by Qiagen N.V., a company traded on the stock exchange under the ticker QGEN. Qiagen is conducting a Phase 2 clinical trial of NEU-411 in patients with early Parkinson's disease.
NEU-411 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 study is recruiting participants with early Parkinson's disease who are positive for a companion diagnostic biomarker.
NEU-411 is being evaluated in a Phase 2 study with the identifier NCT06680830. This trial is a randomized, double-blind, placebo-controlled study that includes an open-label extension. It is recruiting 150 participants with early Parkinson's disease across the United States, Israel, Italy, Poland, Spain, and the United Kingdom.
Yes, NEU-411 is being studied in a biomarker-selected population. The Phase 2 trial enrolls participants who test positive for a companion diagnostic, meaning the study is designed to evaluate the drug specifically in patients identified by this biomarker. This approach aims to target the therapy to a defined patient subgroup.
The NEU-411 Phase 2 trial, NCT06680830, is a randomized, double-blind, placebo-controlled study with an open-label extension. It enrolls 150 participants aged 40 years and older with early Parkinson's disease. The trial is actively recruiting and is being conducted in multiple countries including the United States, Israel, and several European nations.